In a report published Tuesday, Morgan Stanley analyst David Friedman downgraded Alnylam Pharmaceuticals ALNY to Overweight from Equal-weight, raising its price target to $72.00 from $54.00.
According to the report, the move was based on a more balanced risk/reward post recent stock strength.
“We view Alnylam's technology as potentially transformative and see the prospects for the drugs
that have been tested in humans as robust,” the report noted. “In addition, we view the recent Sanofi/Sirna transactions as steps that likely will help maximize the platform from many perspectives. However, in light of the recent stock strength over the past 12 mos, we see a more balanced risk/reward for shares heading into the major TTR program data catalysts in 2H14. Above- expectations TTR data in 2H14 or human proof of concept from an earlier-stage program (e.g. hemophilia) are events that would trigger a valuation re-evaluation.”
ALNY closed Tuesday at $93.28 with shares trading up at 40.89 percent.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in